When Does Polyendocrine Metabolic Ovarian Syndrome (PMOS) Change Definition? A Lifespan Perspective on Menopause and Metabolic Health.
Key claim: Menopause marks a phenotypic shift rather than the resolution of polyendocrine metabolic ovarian syndrome, leaving persistent metabolic dysregulation that accelerates postmenopausal cardiometabolic aging.
Abstract
The evolving concept of Polyendocrine Metabolic Ovarian Syndrome (PMOS) reflects increasing recognition that this condition extends beyond reproductive dysfunction and ovarian morphology to encompass complex interactions among metabolic, endocrine, inflammatory, and cardiometabolic pathways. Although PMOS is most commonly diagnosed during the reproductive years, an increasing number of women with PMOS are now entering perimenopause and menopause, highlighting important limitations of current diagnostic paradigms. Traditional reproductive markers-including ovulatory dysfunction and ovarian morphology-become progressively less informative with advancing age, raising questions about whether the diagnosis remains relevant after menopause. Although ovarian manifestations diminish, many women with a history of PMOS continue to exhibit persistent metabolic and endocrine abnormalities, including insulin resistance, visceral adiposity, dyslipidemia, metabolic dysfunction-associated steatotic liver disease, chronic low-grade inflammation, and elevated cardiovascular risk. Emerging evidence suggests that these metabolic consequences may persist throughout life and contribute to trajectories of accelerated cardiometabolic aging. This review examines the challenges of applying reproductive-age diagnostic frameworks to midlife and older women and proposes a lifespan model in which PMOS evolves from a predominantly ovarian and reproductive syndrome into a broader metabolic-endocrine phenotype. We explore the clinical implications of this transition for risk assessment, long-term surveillance, and therapeutic decision-making during perimenopause and beyond. As understanding of PMOS continues to evolve, menopause may represent a shift rather than the end of the syndrome in its clinical expression. Reframing PMOS as a dynamic lifespan condition may provide a more comprehensive approach to the care of women with aging and support the development of age-appropriate diagnostic and management strategies.
Why this matters
[expert-opinion] This review reframes menopause as a change in the expression of a persistent endocrine-metabolic condition rather than its resolution, placing reproductive-age metabolic history within the causal discussion of postmenopausal cardiometabolic aging. [expert-opinion] The lifespan model does not establish accelerated biological aging in humans, an inflammatory mediator, or benefit from hormone-based or metabolic interventions.